Skip to main content
. 2021 Apr 23;218(6):e20210008. doi: 10.1084/jem.20210008

Figure 5.

Figure 5.

Cardioprotection of netrin-1 is myeloid ADORA2B dependent. (A) Surgery and netrin-1 treatment strategy. Recombinant mouse netrin-1 or PBS was given i.v. 5 min before reperfusion. (B) Infarct sizes of Adora2bloxP/loxP VE-cadherin Cre+ mice compared with VE-cadherin Cre+ mice (n = 6 per group; two-tailed unpaired t test). (C, F, and I) Representative infarct staining results of Adora2bloxP/loxP Cre+ and corresponding Cre+ mice. The infarct area is outlined by a green line, and the blue line marks the AAR (scale bar = 1 mm). (D) cTnI levels of Adora2bloxP/loxP VE-cadherin Cre+ mice compared with VE-cadherin Cre+ (n = 6 and 5 for PBS and netrin-1 treatment groups, respectively; two-tailed unpaired t test). (E) Infarct sizes of Adora2bloxP/loxP Myosin Cre+ mice compared with Myosin Cre+ mice (n = 6 per group; two-tailed unpaired t test). (G) cTnI levels of Adora2bloxP/loxP Myosin Cre+ mice compared with Myosin Cre+ (n = 6 per group; two-tailed Welch’s t test). (H) Infarct sizes of Adora2bloxP/loxP Lyz2 Cre+ mice compared with Lyz2 Cre+ mice (n = 7 and 8 for PBS and netrin-1 treatment groups, respectively; two-tailed unpaired t test). (J) cTnI levels of Adora2bloxP/loxP Lyz2 Cre+ mice compared with Lyz2 Cre+ (n = 7 and 8 for PBS and netrin-1 treatment groups, respectively; two-tailed unpaired t test). ****, P < 0.0001; *, P < 0.05. Data are presented as mean ± SD.